Tenofovir (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tenofovir" in Italian language version.

refsWebsite

Global rank Italian rank

14nih.gov

4^th place

9^th place

7doi.org

2^nd place

7^th place

6archive.org

6^th place

8^th place

4oadoi.org

799^th place

22^nd place

archive.org

SA. Grim, F. Romanelli, Tenofovir disoproxil fumarate., in Ann Pharmacother, vol. 37, n. 6, giugno 2003, pp. 849-59, PMID 12773076.
P. Barditch-Crovo, SG. Deeks; A. Collier; S. Safrin; DF. Coakley; M. Miller; BP. Kearney; RL. Coleman; PD. Lamy; JO. Kahn; I. McGowan, Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults., in Antimicrob Agents Chemother, vol. 45, n. 10, ottobre 2001, pp. 2733-9, DOI:10.1128/AAC.45.10.2733-2739.2001, PMID 11557462.
BL. Robbins, RV. Srinivas; C. Kim; N. Bischofberger; A. Fridland, Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA., in Antimicrob Agents Chemother, vol. 42, n. 3, marzo 1998, pp. 612-7, PMID 9517941.
R. Hazra, FM. Balis; AN. Tullio; E. DeCarlo; CJ. Worrell; SM. Steinberg; JF. Flaherty; K. Yale; M. Poblenz; BP. Kearney; L. Zhong, Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children., in Antimicrob Agents Chemother, vol. 48, n. 1, gennaio 2004, pp. 124-9, PMID 14693529.
G. Woo, G. Tomlinson; Y. Nishikawa; M. Kowgier; M. Sherman; DK. Wong; B. Pham; WJ. Ungar; TR. Einarson; EJ. Heathcote; M. Krahn, Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses., in Gastroenterology, vol. 139, n. 4, ottobre 2010, pp. 1218-29, DOI:10.1053/j.gastro.2010.06.042, PMID 20600036.
P. Pecora Fulco, MA. Kirian, Effect of tenofovir on didanosine absorption in patients with HIV., in Ann Pharmacother, vol. 37, n. 9, settembre 2003, pp. 1325-8, DOI:10.1345/aph.1C412, PMID 12921517.

doi.org

dx.doi.org

P. Barditch-Crovo, SG. Deeks; A. Collier; S. Safrin; DF. Coakley; M. Miller; BP. Kearney; RL. Coleman; PD. Lamy; JO. Kahn; I. McGowan, Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults., in Antimicrob Agents Chemother, vol. 45, n. 10, ottobre 2001, pp. 2733-9, DOI:10.1128/AAC.45.10.2733-2739.2001, PMID 11557462.
C. Lu, Y. Jia; L. Chen; Y. Ding; J. Yang; M. Chen; Y. Song; X. Sun; A. Wen, Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers., in J Clin Pharm Ther, dicembre 2012, DOI:10.1111/jcpt.12023, PMID 23278367.
PA. Pham, JE. Gallant, Tenofovir disoproxil fumarate for the treatment of HIV infection., in Expert Opin Drug Metab Toxicol, vol. 2, n. 3, giugno 2006, pp. 459-69, DOI:10.1517/17425255.2.3.459, PMID 16863446.
G. Woo, G. Tomlinson; Y. Nishikawa; M. Kowgier; M. Sherman; DK. Wong; B. Pham; WJ. Ungar; TR. Einarson; EJ. Heathcote; M. Krahn, Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses., in Gastroenterology, vol. 139, n. 4, ottobre 2010, pp. 1218-29, DOI:10.1053/j.gastro.2010.06.042, PMID 20600036.
J. Jones, J. Colquitt; J. Shepherd; P. Harris; K. Cooper, Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection., in Health Technol Assess, 14 Suppl 1, maggio 2010, pp. 23-9, DOI:10.3310/hta14Suppl1/04, PMID 20507800.
CM. Perry, D. Simpson, Tenofovir disoproxil fumarate: in chronic hepatitis B., in Drugs, vol. 69, n. 16, novembre 2009, pp. 2245-56, DOI:10.2165/10482940-000000000-00000, PMID 19852527.
P. Pecora Fulco, MA. Kirian, Effect of tenofovir on didanosine absorption in patients with HIV., in Ann Pharmacother, vol. 37, n. 9, settembre 2003, pp. 1325-8, DOI:10.1345/aph.1C412, PMID 12921517.

nih.gov

ncbi.nlm.nih.gov

HB. Fung, EA. Stone; FJ. Piacenti, Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection., in Clin Ther, vol. 24, n. 10, ottobre 2002, pp. 1515-48, PMID 12462284.
SA. Grim, F. Romanelli, Tenofovir disoproxil fumarate., in Ann Pharmacother, vol. 37, n. 6, giugno 2003, pp. 849-59, PMID 12773076.
P. Barditch-Crovo, SG. Deeks; A. Collier; S. Safrin; DF. Coakley; M. Miller; BP. Kearney; RL. Coleman; PD. Lamy; JO. Kahn; I. McGowan, Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults., in Antimicrob Agents Chemother, vol. 45, n. 10, ottobre 2001, pp. 2733-9, DOI:10.1128/AAC.45.10.2733-2739.2001, PMID 11557462.
C. Lu, Y. Jia; L. Chen; Y. Ding; J. Yang; M. Chen; Y. Song; X. Sun; A. Wen, Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers., in J Clin Pharm Ther, dicembre 2012, DOI:10.1111/jcpt.12023, PMID 23278367.
BL. Robbins, RV. Srinivas; C. Kim; N. Bischofberger; A. Fridland, Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA., in Antimicrob Agents Chemother, vol. 42, n. 3, marzo 1998, pp. 612-7, PMID 9517941.
R. Hazra, FM. Balis; AN. Tullio; E. DeCarlo; CJ. Worrell; SM. Steinberg; JF. Flaherty; K. Yale; M. Poblenz; BP. Kearney; L. Zhong, Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children., in Antimicrob Agents Chemother, vol. 48, n. 1, gennaio 2004, pp. 124-9, PMID 14693529.
KA. Lyseng-Williamson, NA. Reynolds; GL. Plosker, Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection., in Drugs, vol. 65, n. 3, 2005, pp. 413-32, PMID 15669881.
JE. Gallant, PA. Pham, Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection., in Expert Rev Anti Infect Ther, vol. 1, n. 3, ottobre 2003, pp. 415-22, PMID 15482138.
PA. Pham, JE. Gallant, Tenofovir disoproxil fumarate for the treatment of HIV infection., in Expert Opin Drug Metab Toxicol, vol. 2, n. 3, giugno 2006, pp. 459-69, DOI:10.1517/17425255.2.3.459, PMID 16863446.
G. Woo, G. Tomlinson; Y. Nishikawa; M. Kowgier; M. Sherman; DK. Wong; B. Pham; WJ. Ungar; TR. Einarson; EJ. Heathcote; M. Krahn, Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses., in Gastroenterology, vol. 139, n. 4, ottobre 2010, pp. 1218-29, DOI:10.1053/j.gastro.2010.06.042, PMID 20600036.
J. Jones, J. Colquitt; J. Shepherd; P. Harris; K. Cooper, Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection., in Health Technol Assess, 14 Suppl 1, maggio 2010, pp. 23-9, DOI:10.3310/hta14Suppl1/04, PMID 20507800.
CM. Perry, D. Simpson, Tenofovir disoproxil fumarate: in chronic hepatitis B., in Drugs, vol. 69, n. 16, novembre 2009, pp. 2245-56, DOI:10.2165/10482940-000000000-00000, PMID 19852527.
T. Chapman, J. McGavin; S. Noble, Tenofovir disoproxil fumarate., in Drugs, vol. 63, n. 15, 2003, pp. 1597-608, PMID 12887265.
P. Pecora Fulco, MA. Kirian, Effect of tenofovir on didanosine absorption in patients with HIV., in Ann Pharmacother, vol. 37, n. 9, settembre 2003, pp. 1325-8, DOI:10.1345/aph.1C412, PMID 12921517.

oadoi.org

C. Lu, Y. Jia; L. Chen; Y. Ding; J. Yang; M. Chen; Y. Song; X. Sun; A. Wen, Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers., in J Clin Pharm Ther, dicembre 2012, DOI:10.1111/jcpt.12023, PMID 23278367.
PA. Pham, JE. Gallant, Tenofovir disoproxil fumarate for the treatment of HIV infection., in Expert Opin Drug Metab Toxicol, vol. 2, n. 3, giugno 2006, pp. 459-69, DOI:10.1517/17425255.2.3.459, PMID 16863446.
J. Jones, J. Colquitt; J. Shepherd; P. Harris; K. Cooper, Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection., in Health Technol Assess, 14 Suppl 1, maggio 2010, pp. 23-9, DOI:10.3310/hta14Suppl1/04, PMID 20507800.
CM. Perry, D. Simpson, Tenofovir disoproxil fumarate: in chronic hepatitis B., in Drugs, vol. 69, n. 16, novembre 2009, pp. 2245-56, DOI:10.2165/10482940-000000000-00000, PMID 19852527.